Innovent Buys Into Ascentage, Opening New China Biopharma Chapter
Combining Small, Large Molecule Expertise
Executive Summary
The unprecedented deal between two public Chinese biotechs, Innovent Biologics and Ascentage Pharma, potentially provides an opening for more such mega-million dollar deals to come.
You may also be interested in...
Two Chinese IPOs Kickstart A Hectic Biotech Fundraising Season
Two IPOs and 12 venture capital and private equity deals in China raised a combined $1bn in a hectic few weeks of October.
ADC Competition Heats Up In China But Caution, Pressure Also Mount
After the anti-PD-1/L1 antibody and cell therapy rush, antibody-drug conjugates are quickly gaining attention in China as new technologies and deal-making activity heats up, but one first mover warns of potential over-crowding.
Shanghai Kick-Starts New Consortium To Develop First-In-Class Cancer Drugs
A concerted effort to mobilize the pharma industry, research organizations and state-backed healthcare venture capital firms is under way in Shanghai.